Hyperuricemia and renal function

被引:92
作者
Ruilope L.M. [1 ]
Garcia-Puig J. [1 ]
机构
[1] Unidad de Hipertensión, Hospital 12 de Octubre, 28041, Madrid
关键词
Uric Acid; Gout; Essential Hypertension; Serum Uric Acid; Hyperuricemia;
D O I
10.1007/s11906-001-0038-2
中图分类号
学科分类号
摘要
Increased serum urate concentration is commonly seen in clinical practice. It does not represent a specific disease, nor is it an indication for therapy. Hyperuricemia can be the consequence of increased uric acid production and/or decreased renal capacity to excrete uric acid. In essential hypertension, it has been described in up to one third of patients and is directly related to an increase in renal vascular resistance and inversely correlated with renal plasma flow. In other words, abnormal renal hemodynamics, commonly seen in the initial stages of the disease, account for the increased serum urate concentration. This can be maintained if a decrease in glomerular filtration rate takes place. The increase in uric acid has been shown to be a potent predictor of the development of cardiovascular events and death. In addition, uric acid, particularly when elevated, could represent an independent risk factor. On the other hand, an altered renal function predicts in an independent manner a higher cardiovascular risk. For this reason, the predictive capacity of uric acid could be partly dependent on the fact that hyperuricemia runs in parallel with a deranged renal function. Copyright © 2001 by Current Science Inc.
引用
收藏
页码:197 / 202
页数:5
相关论文
共 65 条
[1]  
Hall A.P., Barry P.E., Dawber T.R., McNamara P.M., Epidemiology of gout and hyperuricemia: A long term population study, Am J Med, 42, pp. 27-37, (1967)
[2]  
Zalokar J., Lellouch J., Claude J.R., Serum urate and gout in 4663 young male workers, Semin Hôp Paris, 57, pp. 664-668, (1981)
[3]  
Noguera Hernando E., Estudio epidemiológico de hiperuricemia y gota en España, Fase I. Madrid: Saned, pp. 8-19, (1987)
[4]  
Paulus H.E., Coutts A., Calabro J.J., Klinenberg J.R., Clinical significance of hyperuricemia in routinely screened hospitalized men, JAMA, 211, pp. 277-281, (1970)
[5]  
Allen D.J., Milosovich G., Mattock A.M., Inhibition of monosodium urate crystal growth, Arthritis Rheum, 8, pp. 1123-1133, (1965)
[6]  
Campion E.W., Glynn R.J., DeLabry L.O., Asymptomatic hyper-uricemia. Risks and consequences in the normative aging study, Am J Med, 82, pp. 421-426, (1987)
[7]  
Mikkelsen W.M., Dodge H.J., Valkenburg H., The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia. Tecumseh, michigan, 1959-1960, Am J Med, 39, pp. 242-251, (1965)
[8]  
Nichols A., Suaith M.L., Scott J.T., Effect of oestrogen therapy on plasma and urinary levels of uric acid, BMJ, 1, pp. 449-451, (1973)
[9]  
Mateos Anton F., Garcia Puig J., Ramos T., Et al., Sex differences in uric acid metabolism in adults: Evidence for a lack of influence of estradiol - 17Beta (e2) on the renal handling of urate, Metabolism, 35, pp. 343-248, (1986)
[10]  
Puig J.G., Michan A.D., Jimenez M.L., Et al., Female gout. Clinical spectrum and uric acid metabolism, Arch Intern Med, 151, pp. 726-732, (1991)